Transplant Rejection
9
2
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Immunological Mechanisms of Rejection in Uterine Transplantation
Study of the Plasma and Urinary cfDNA of in Kidney Transplant Patients
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Rejection Diagnosis in Kidney Transplants Patients
Study of Tolerant Kidney Transplant Recipients
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients